Insulin Resistance in HIV Lipodystrophy Syndrome
The identification of an increased incidence of insulin resistance among HIV-infected patients has raised concern that this population in general, and individuals with evidence of fat redistribution in particular, may be at increased risk for developing diabetes and cardiovascular disease. Recent data suggest that insulin-sensitizing agents may improve the metabolic abnormalities associated with HIV lipodystrophy syndrome. In this article, we will review the incidence and potential clinical consequences of and therapeutic strategies for insulin resistance in HIV disease.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)